Anti-Asthmatics And COPD Drugs Global Market Sees Growth Rate Of 9% Through 2022

The global anti-asthmatics and COPD drugs market size is expected to grow from $80.73 billion in 2021 to $88.18 billion in 2022 at a compound annual growth rate (CAGR) of 9.2%. The change in the anti-asthmatic and COPD drug market growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The global market is expected to reach $118.78 billion in 2026 at a CAGR of 7.7%.

What is the Global Anti-Asthmatics And COPD Drugs Market?

The anti-asthmatics and chronic obstructive pulmonary disease (COPD) market consists of sales of anti-asthmatics and chronic obstructive pulmonary disease (COPD) drugs which are used to relieve the frequency of acute attacks of asthma, emphysema, chronic bronchitis, and nocturnal awakenings.

Get a Sample of the global anti-asthmatics and COPD drugs market report
https://www.thebusinessresearchcompany.com/sample.aspx?id=3802&type=smp

What drives the Global Anti-Asthmatics And COPD Drugs Market?

Modifiable risk factors including smoking, lack of physical exercise, and unhealthy eating habits drive the Asthma and COPD drugs market. Even though there is a decreasing trend of smoking prevalence globally, developing countries such as China, India, Indonesia, and Nigeria among others have increasing smoking prevalence. For instance, the number of tobacco smokers is set to increase by 24 million in Indonesia and by 7 million in Nigeria by 2025, and more than 40% of global cigarette consumption is concentrated in China. Consumption of fats including saturated fatty acids which is a risk factor for Asthma and COPD is more in high income countries including USA and Europe. According to WHO, in developed countries more than 35% of total energy requirement is derived from fats when compared to <20% in low income countries, and <25% in lower middle income countries.

Get the full global anti-asthmatics and COPD drugs industry report here

Global Anti-Asthmatics And COPD Drugs Market Segments
The global anti-asthmatics and COPD drugs market is segmented:
By Type: Anti-Histamine Drugs, Long-Acting ß2-Agonists (LABA), Inhaled Corticosteriods, Short-Acting Muscarinic Receptor Antagonists (SAMAs), Others (including Combinations)
By Drug Class: Bronchodilators, Anti-inflammatory Drugs, Monoclonal Antibodies, Combination Drugs
By End-User: Asthma Patients, COPD Patients
By Distribution Channel: Hospital Pharmacies, Private Clinics, Drug Stores, Retail Pharmacies, E-Commerce
By Geography: The regions covered in the anti-asthmatics and COPD drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Anti-Asthmatics And COPD Drugs Global Market Report 2022 provides market size and growth forecasts for the global anti-asthmatics and COPD drugs market, global anti-asthmatics and COPD drugs market share, anti-asthmatics and COPD drugs market segments and geographies, anti-asthmatics and COPD drugs market competitive landscape including leading competitors’ revenues, profiles and anti-asthmatics and COPD drugs market shares. The anti-asthmatics and COPD drugs market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.

Global Anti-Asthmatics And COPD Drugs Industry Players include Novartis AG, Merck & Co, GlaxoSmithKline, Boehringer Ingelheim Gmbh, AstraZeneca, Roche, Teva Pharmaceutical, Vectura, Pfizer and Abbott. Based on industry trends and company analysis, the report explains a number of strategies for companies in the market.